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Abbreviations 
AgRP, agouti related protein; BAT, brown adipose tissue; D2, type 2 iodothyronine 
deiodinase; Egr-1, early growth response gene-1; NPY, neuropeptide Y; POMC, pro-
opiomelanocortin; PVN, paraventricular nucleus; RPA, ribonuclease protection assay; 
T3, tri-iodothyronine; T4, thyroxine; UCP-1, uncoupling protein-1; VMN, ventromedial 
nucleus; VO2, oxygen consumption; WAT, white adipose tissue.
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Abstract 
Increased food intake is characteristic of hyperthyroidism, although this is presumed to 
compensate for a state of negative energy balance. However, here we show that the 
thyroid hormone tri-iodothyronine (T3) directly stimulates feeding at the level of the 
hypothalamus. Peripheral administration of T3 doubled food intake in ad libitum fed 
rats over 2 hours and induced expression of the immediate early gene, Egr-1, in the 
hypothalamic ventromedial nucleus (VMN), whilst maintaining plasma fT3 levels 
within the normal range. T3-induced feeding occurred without altering energy 
expenditure or locomotion. Injection of T3 directly into the VMN produced a four-fold 
increase in food intake in the first hour. The majority of T3 in the brain is reported to be 
produced by tissue-specific conversion of T4 to T3 by the enzyme type 2 iodothyronine 
deiodinase (D2). Hypothalamic D2 mRNA expression showed a diurnal variation, with 
a peak in the nocturnal feeding phase. Hypothalamic D2 mRNA levels also increased 
following a 12- and 24 hour fast, suggesting that local production of T3 may play a role 
in this T3 feeding circuit. Thus, we propose a novel hypothalamic feeding circuit in 
which T3, from the peripheral circulation or produced by local conversion, stimulates 
food intake via the VMN. 
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In hyperthyroidism, elevated plasma levels of thyroid hormones increase energy 
expenditure and decrease body weight (1). It is widely assumed that the characteristic 
increased appetite of hyperthyroidism is compensatory for this state of negative energy 
balance. Interestingly, about 5-10% of hyperthyroid individuals have a sufficiently 
increased appetite to gain weight in spite of the catabolic thyrotoxic process (2), 
suggesting that thyroid hormones may directly stimulate feeding.  
 
T3 is the biologically active thyroid hormone. Tissue T3 concentrations are controlled at 
the cellular level and may not reflect plasma thyroid hormone concentrations (3). Thus, 
within the rat central nervous system (CNS), physiological levels of T3 are largely 
dependent on cellular uptake and intracellular deiodination of T4 to T3 by D2 (4,5). 
Within the hypothalamus, D2 mRNA (6,7) and activity (8) are concentrated in the 
periventricular region of the third ventricle, the arcuate nucleus (ARC) and median 
eminence. D2 mRNA is localised to tanycytes, specialised ependymal cells, lining the 
third ventricle (9). Tanycytes have long cytoplasmic processes projecting to several 
hypothalamic nuclei, including the ARC and the ventromedial nucleus (VMN) (10). The 
function of this local hypothalamic T3 production is unknown.  
 
The hypothalamus plays an essential role in the regulation of energy homeostasis, 
integrating signals from other areas of the CNS and the periphery. Several hypothalamic 
nuclei have been implicated in the regulation of food intake and energy balance 
including the ARC, paraventricular nucleus (PVN) and VMN. Within the ARC two 
important neuronal populations have been identified: appetite inhibiting pro-
opiomelanocortin (POMC) expressing neurons and appetite stimulating neuropeptide Y 
(NPY) and agouti related protein (AgRP) co-expressing neurons (11). Both of these 
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neuronal populations project to the PVN. The VMN was labelled as a satiety centre over 
50 years ago when studies demonstrated that lesioning the VMN resulted in 
hyperphagia and weight gain (12). However more recent studies suggest that the role of 
the VMN in appetite regulation is more complex. The VMN receives and sends out 
extensive projections to other regions of the hypothalamus including the PVN and 
dorsomedial hypothalamus and may modulate the release of orexigenic signals from 
these hypothalamic nuclei (13).  
 
The effects of overt hyperthyroidism and hypothyroidism on energy homeostasis and 
appetite have been well-established in rodents and man (14-16). However, such states 
are associated with marked effects on behavior and metabolism. Therefore it is not 
possible to infer from these studies a physiological role for thyroid hormones in the 
regulation of food intake. To investigate a role for T3 in the physiological regulation of 
food intake, we studied the effects of peripheral and CNS administration of T3, using 
doses of T3 which did not elevate plasma fT3 levels outside of the normal range 
(referred to as ‘low-dose’ T3 for the remainder of the paper). We examined the effects 
of low-dose T3 on food intake, energy expenditure and behavior. In addition, we 
studied diurnal variation and the effect of short-term fasting on hypothalamic D2 
mRNA expression. 
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Methods 
Animal Care and Maintenance  
Male Wistar rats (ICSM, London, UK) (200-250g) aged 7-8 weeks were maintained 
under standardized barrier conditions (21-23oC, lights on 07:00–19:00) and fed ad 
libitum RM1 diet (SDS Ltd., Witham, UK) unless described otherwise. All animal 
procedures were conducted under the British Home Office Animals (Scientific 
Procedures) Act (1986). All injections were administered in the early light phase 
(07:00-09:00).  
 
T3 preparation for peripheral administration 
For peripheral (subcutaneous (s.c.)) injections, T3 was prepared as 3, 3’, 5-triiodo-L-
thyronine (T3) (Sigma, Dorset, UK) dissolved in absolute ethanol and emulsified in 
safflower oil (1:10) (volume 0.1ml). Controls received vehicle (emulsion alone). Prior 
to all studies, animals received 2 sham s.c. saline injections.  
 
Peripheral administration of T3 and food intake 
In the acute study of the effects of T3 on food intake, animals received either s.c. T3 
(1.1, 2.3 or 4.5 nmol/kg) or s.c. vehicle (n = 12 per group). Food was weighed at 2, 4, 8 
and 24 hours post-injection. In a separate study, animals received s.c. T3 (4.5 nmol/kg) 
or vehicle (controls) and were killed 2 hours post-injection by decapitation for 
collection of trunk blood as described (17). In the chronic study, animals (n = 12 per 
group) were injected with s.c. T3 (4.5, 9 or 75 nmol/kg) or s.c. vehicle daily for 5 days. 
On day 5 trunk blood was collected. Brains were removed and hypothalami dissected 
out and snap frozen for subsequent measurement of neuropeptide mRNA expression by 
RNase protection assay (RPA) (described below). Interscapular brown adipose tissue 
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(BAT) and epididymal white adipose tissue (WAT) were also collected, then weighed 
and frozen. BAT UCP-1 mRNA expression was measured by RPA. 
 
Radioimmunoassay (RIA) 
Plasma TSH levels were assayed using methods and reagents kindly provided by A. 
Parlow (NIDDK National Hormone and Pituitary Program, Baltimore, MD) as 
previously described (17). Plasma leptin (Linco Research, St. Charles, MO), fT3 and 
fT4 (Diagnostic Products Corp., Los Angeles, CA) were measured using commercial 
RIAs following manufacturer’s instructions. 
 
Behavioral study 
Animals received a s.c. injection of T3 (4.5 nmol/kg) or vehicle at time zero (n = 16 per 
group). Behavioral patterns were monitored continuously from 30 to 120 minutes, by 
observers blinded to the experimental treatment. Behavior was classified into 3 different 
categories (adapted from Abbott (18)); feeding, active non-feeding behavior (drinking, 
grooming, burrowing, rearing, locomotion) and inactive non-feeding behavior (sleeping 
and still). These methods have previously been used to demonstrate abnormal 
behaviours following CNS administration of peptides (18). During the analysis, each rat 
was observed for 12 seconds every 5 minutes. This 12 second period was subdivided 
into 3 and the behavior of the rat during each section of the time period scored (816 
total observations per rat).  
 
 
 
 7
Oxygen consumption (VO ) studies 2  
Indirect calorimetry was used to measure VO2 as an indirect measurement of energy 
expenditure as previously described (19).  VO2 was determined in closed circuit 
respirometers maintained at thermoneutral temperature for rats (29°C). Animals were 
acclimatized to the calorimetry chamber for 2 hours prior to injection (n = 8 per group) 
and injected with T3 or vehicle at time zero. VO2 was measured for 240 minutes after 
treatment. To study of the acute effects of T3 on VO2, calorimetry was performed after a 
single s.c. injection of 4.5 nmol/kg T3 or vehicle. This was repeated following a single 
intraperitoneal (i.p.) injection of the β3-adrenoceptor agonist BRL 35135 (40μg/kg) as a 
positive control (20). To study the effects of chronic T3 administration on VO2, animals 
received 5 days of once daily s.c. injections of T3 (4.5 or 75 nmol/kg) or vehicle, and 
calorimetry was performed on day 5.  
 
Ribonuclease Protection Assay (RPA)  
Total RNA was extracted from hypothalami and BAT collected from animals after a 
single s.c. T3 injection or 5 days of once daily T3 injections (4.5 nmol/kg) (n = 12 per 
group) using Tri-Reagent (Helena Biosciences, Sunderland, UK) following the 
manufacturer’s protocol. Hypothalamic AgRP, POMC, NPY and D2 (all 5µg) and BAT 
UCP-1 (0.25µg) mRNA were quantified by RPA (21) (Ambion RPA III kit, Ambion 
Inc. Austin, TX) using in-house probes (Accession numbers: UCP-1 M11814, AgRP 
U89484, POMC NM_139326, NPY NM_012614 and D2 NM_031720). Rat β-actin was 
used as an internal control (Ambion Inc). RNA was hybridised overnight and separated 
on a 5% polyacrylamide gel. The dried gel was exposed to a phosphoimager screen 
overnight and protected RNA hybrids quantified using ImageQuant software (Molecular 
Dynamics, Sunnyvale, CA).  For each neuropeptide, the ratio of the optical density of 
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the band of neuropeptide mRNA to that of β-actin was calculated and expressed in 
relative units (R.U.) (22). 
 
Immunocytochemistry (ICC)  
Egr-1 immunoreactivity (IR) was measured by ICC in paraffin embedded, 
paraformaldehyde fixed male Wistar rat brains collected 2 hours after s.c. 
administration 4.5 nmol/kg T3 or vehicle (23). Non-specific binding was blocked using 
normal donkey serum and sections incubated in rabbit anti Egr-1 antibody (Santa-Cruz 
Biotechnology, Santa-Cruz, CA) diluted 1:1000, at 4°C overnight. Slides were 
incubated for 30 minutes in biotinylated donkey anti-rabbit secondary antibody (1:50) 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA) followed by a 30 minute 
incubation in ABC-horseradish peroxidase (HRP) (1:100) (Dako Cytomation, Glostrup, 
Denmark). The antigen-antibody complex was visualised with 3,3’-Diaminobenzidine 
(DAB) in 0.01% hydrogen peroxide. Every 5th section was stained with hematoxylin 
and eosin to allow identification of the relevant hypothalamic nuclei.  Egr-1-IR was 
counted by an observer blinded to the experimental treatment using a Nikon Eclipse 
E800 microscope and Image Pro-Plus v 4.5 software (MediaCybernetics, Silver Spring, 
MD).    
 
Intranuclear cannulation and injection of T3 
Animal surgical procedures and handling were carried out as previously described (18). 
Animals were anaesthetised by i.p. injection of a mixture of Ketalar (ketamine HCl 
60mg/kg; Parke-Davis, Pontypool, UK) and Rompun (xylazine 12 mg/kg; Bayer UK 
Ltd, Bury St Edmonds, UK) and placed on a stereotaxic frame (David Kopf 
instruments, Tujunga, CA). Permanent 26 gauge stainless steel guide cannulae (Plastics 
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One Inc., Roanoke, VA) were stereotactically placed into the hypothalamic VMN or 
ARC as previously described (24). Due to its low solubility, T3 was dissolved in 5% 
ethanol. We have previously shown that CNS injection of up to 70% ethanol does not 
produce behavioral abnormalities (25). Animals received 0.5, 1, 5 and 50 pmol T3 or 
vehicle administered in 1µl. Food was weighed at 1, 2, 4, 8 and 24 hours post-injection. 
Cannula placement was verified at the end of the study by the injection of black ink 
(26). Data from an animal was excluded if its injection site extended more than 0.2mm 
outside the intended hypothalamic injection site or if any ink was detected in the 
cerebral ventricular system.   
 
Measurement of D2 mRNA expression 
For the fasting study, hypothalami were dissected and collected from rats either fed ad 
libitum (control) or fasted for 12 or 24 hours (n = 10 per group). For the diurnal 
variation study, rats were killed at 9 time points (n = 10 per group) throughout a 24 hour 
period. Hypothalamic D2 mRNA levels were measured using RPA (as described). 
 
Statistical analysis 
Statistical analyses were carried out in collaboration with David Stephens (Department 
of Mathematics, Imperial College London). Values are presented as the mean ± SEM 
unless otherwise stated. Behavioral data are presented as % of total observations ± 
estimated standard error. A Bayesian analysis was used to compare the relative 
probabilities of each behavioral profile in each group. For VO2 studies, groups of data 
were compared using a two-way ANCOVA (S-plus, Seattle, WA). For Egr-1 studies 
(data expressed as median values with interquartile ranges), a Wilcoxon non-parametric 
test was used. In the remaining studies, comparisons were made using ANOVA, with 
 10
post hoc Fisher’s Least Significant Difference method (Systat, Evanston, IL). Normal 
ranges (mean ± 2SD) for thyroid hormones were calculated within our laboratory from 
euthyroid control rats. Polynomial regression analysis was used for studying D2 mRNA 
diurnal rhythm (SigmaStat 2.03, Chicago, IL). P values < 0.05 were considered 
significant. 
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Results 
Acute Effects of Peripheral T3 on Food Intake, Plasma Hormones and Behavior
Two hours post-s.c. injection of T3 (4.5 nmol/kg), food intake increased by 140% (1.2 ± 
0.3 [T3] vs. 0.5 ± 0.1g [control], P < 0.05) (Fig. 1A). This stimulatory effect persisted 
for 8 hours (5-8 hours: 1.3 ± 0.4 [T3] vs. 0.6 ± 0.1g [control], P < 0.05) (Fig. 1B). 
Lower doses of T3 had no effect on feeding. Twenty four hours post-injection, there 
was no difference in food intake between T3-treated and control animals. 
 
Plasma leptin levels were unchanged 2 hours following T3 treatment (4.5 nmol/kg) (2.8 
± 0.2 [T3] vs. 2.9 ± 0.3 ng/ml [control]). Plasma fT3 was 46% higher in the T3-treated 
group compared to controls (3.5 ± 0.2 [T3] vs. 2.4 ± 0.2 pmol/L [control], P<0.001), yet 
remained within the normal range (1.2 - 3.6 pmol/L). There was no difference in plasma 
fT4 (15.3 ± 0.6 [T3] vs. 15.7 ± 0.5 pmol/L [control]) or TSH (2.9 ± 0.3 [T3] vs. 3.5 ± 
0.4 ng/ml [control]) in T3-treated animals compared to controls.  
 
T3-treated (4.5 nmol/kg) animals spent over twice as much time feeding than control 
animals (5.3 ± 0.8 [T3] vs. 2.2 ± 0.5 % total observations [control], P < 0.005). Notably, 
there were no significant differences in active non-feeding behaviors (including 
locomotion) between the 2 groups (15.6 ± 1.3 [T3] vs. 15.3 ± 1.3 % total observations 
[control]). No adverse behaviors were observed at any time.  
 
Chronic Effects of Peripheral T3 on Food Intake, Body Weight and Body 
Adiposity 
T3 was administered (s.c) once daily for 5 days at a dose of 4.5, 9 or 75 nmol/kg. Mean 
daily food intake on day 5 was significantly greater in the 4.5 nmol/kg T3 and 9 
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nmol/kg T3 groups (30.1 ± 0.4 [4.5 nmol/kg T3], 29.1 ± 0.7 [9nmol/kg] and 27.3 ± 0.4g 
[control], (P < 0.005, 4.5 nmol/kg T3 vs. control), (P < 0.05, 9nmol/kg T3 vs. control) 
(Fig. 2A). 4.5 nmol/kg T3 also significantly increased cumulative food intake (days 0-5: 
116.0 ± 1.7 [T3] vs. 107.6 ± 1.9g [control], P < 0.05) (Fig. 2B). The highest dose of T3, 
75 nmol/kg, did not increase feeding. Consistent with the increased food intake, 
cumulative weight gain was 30% greater in the 4.5 nmol/kg T3 group, although this did 
not reach statistical significance (day 5: 23.3 ± 1.6 [T3] vs. 18.2 ± 2.1g [control], P = 
0.1) (Fig. 2C).  
 
The effects of chronic administration of T3 on body adiposity, plasma leptin and thyroid 
hormones are shown in Table 1. Chronic treatment with 4.5 nmol/kg T3 also increased 
plasma fT3 by 40%, although this remained within the normal range. Plasma TSH was 
lowered by 20% (P < 0.05) compared to controls but again remained within the normal 
range. Although 9 nmol/kg T3 had some stimulatory effects on feeding, this was 
associated with suppression of the thyroid axis (Table 1). The highest dose of T3, 75 
nmol/kg, produced a five-fold increase in plasma fT3 (P < 0.0005), with marked 
suppression of TSH consistent with significant thyrotoxicosis. Chronic administration 
of 4.5 mol/kg T3 did not alter plasma leptin, interscapular BAT mass or interscapular 
BAT uncoupling protein -1 (UCP-1) mRNA levels (20.0 ± 2.3 [T3] vs. 19.0 ± 2.1 
relative units [control]). 
 
Effects of acute and chronic peripheral administration of T3 on energy 
expenditure 
Following a single injection of T3 (4.5 nmol/kg), oxygen consumption (VO ) was 
unchanged compared to control animals (Fig. 3A). However, an i.p. injection of the β -
2
3
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adrenoreceptor agonist BRL 35135 significantly increased VO  as previously reported 2
(20) (Fig. 3B). Similarly, once daily injection of 4.5 nmol/kg T3 for 5 days did not alter 
day 5 VO (Fig. 4A). Following chronic daily administration of 75nmol/kg T3, basal 
VO  had significantly increased (day 5: 18.7 ± 0.5 [T3] vs. 15.8 ± 0.5ml/kg /min 
[control], P < 0.005) and it was further increased 30 minutes after T3 injection (21.1 ± 
0.4 [T3] vs. 16.5 ± 0.7 ml/kg /min [control], P < 0.0005) (Fig. 4B). This elevation in 
VO  remained evident for the duration of VO  measurement (240 minutes). 
2 
2
0.75
0.75
2 2
 
Effects of acute and chronic peripheral T3 treatment on hypothalamic 
neuropeptide mRNA expression 
Following a single injection of T3 (4.5 nmol/kg), hypothalamic POMC mRNA, AgRP 
mRNA and NPY mRNA levels were unchanged compared to control animals (data not 
shown). This was also true of 5 days of daily administration of T3 (4.5, 9, 75 nmol/kg) 
(Table 1).  
 
Determination of neuronal activation following peripheral T3 injection.
Within the CNS, T3 induces expression of the early growth response (Egr) family of 
transcription factors (27, 28), yet may inhibit c-fos expression (29, 30). Therefore, to 
investigate a potential hypothalamic site of action for peripheral T3, Egr-1-IR was 
examined. Peripheral T3 injection was associated with a significant increase in the 
number of cells positive for Egr-1 in the VMN (median value and [interquartile range]: 
1080 [879:1282] [T3] vs. 642 [620:664] immunoreactive cells [control], P < 0.05 (Figs. 
5A and B). No change in Egr-1–IR was detected within the ARC (511 [367:656] [T3] 
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vs. 399 [378:420] immunoreactive cells [control]). No Egr-1-IR was observed in the 
PVN post-T3 administration. See Supplemental Data for representative images. 
 
Effects of intranuclear administration of T3 on food intake 
In view of the findings from these ICC studies, we studied the effects of injection of T3 
(0.5, 1, 5 or 50 pmol) directly into the VMN. All doses of T3 significantly increased 
food intake 1 hour post-injection (Fig. 5C). Fifty picomoles T3 produced a four-fold 
stimulation in feeding (0-1h: 3.1 ± 0.5 [50 pmol T3] vs. 0.8 ± 0.2g [control], P < 
0.0001). This stimulatory effect on food intake was short-lived. Food intake between 1-
2 and 2-4 hours post-injection was unchanged compared to controls. In contrast, intra-
ARC injection of T3 did not alter food intake at any dose (P = 0.3). 
 
Hypothalamic D2 mRNA expression 
Effect of fasting  
In animal fasted for 12 and 24 hours, hypothalamic D2 mRNA expression was 
increased by approximately 50% compared to fed controls (5.9 ± 0.6 [12h fast] vs. 4.0 ± 
0.5 relative units [fed], P <0.05), (6.1 ± 0.9 [24h fast] vs. 4.0 ± 0.5 relative units [fed], P 
< 0.05) (Fig. 6A). 
 
Diurnal variation 
Hypothalamic D2 mRNA expression exhibited a diurnal rhythm (Fig. 6B), reaching a 
nadir at 15:00 hours, 8 hours after lights on. Subsequently, D2 mRNA expression 
progressively increased, with maximal levels at 23:00 hours, 4 hours after lights out. 
This peak D2 mRNA expression was significantly greater than all other light-phase 
time-points (P < 0.05). A three-fold change in D2 mRNA expression was observed 
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through the 24 hour period. Trend analysis by polynomial fit revealed a cubic 
relationship between D2 mRNA expression and time of day (P = 0.001). 
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Discussion 
We have demonstrated a novel role for T3 in the stimulation of food intake. This effect 
was seen using T3 doses substantially lower than those used by other groups (14, 31). In 
our study, plasma fT3 levels were increased by approximately 40%, but remained within 
the normal range following acute and chronic peripheral administration of 4.5 nmol/kg 
T3. In contrast, the higher doses of T3 produced up to a five-fold increase in plasma fT3 
and were associated with a marked suppression of plasma fT4 and TSH. 
Supraphysiological levels of T3 are likely to result in metabolic and behavioral changes 
that would make the effects on food intake difficult to interpret. Therefore, in our 
experiments studying the effects of low-dose T3 on feeding, we were careful to adjust the 
dose of T3 to maintain fT3 levels within the normal range.  
 
In our studies, we peripherally administered T3, the biologically active thyroid hormone, 
which readily crosses the blood brain barrier (32, 33). Our results support a direct effect 
of T3 on feeding, since this stimulation occurred in the absence of changes in energy 
expenditure, behavior or plasma leptin. The chronic orexigenic effect of T3 is unlikely to 
be a compensatory response to weight loss, since our data showed that the dose of T3 
which stimulated feeding (4.5nmol/kg) was actually associated with a trend towards 
increased weight gain.  The well characterised effects of thyroid hormones are mediated 
by nuclear hormone receptors via activation of gene transcription and occur over a period 
of hours to days (34). However, a number of thyroid hormone effects occur more rapidly 
and are independent of the cell nucleus (34, 35). These non-genomic effects of thyroid 
hormones have been described in a variety of tissues (36-39). The rapid increase in 
feeding following T3 injection observed in the current study suggests such a non-
genomic effect. 
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In rodents, BAT is the major site of adaptive thermogenesis due to the expression of 
uncoupling proteins (UCPs). UCP-1 is exclusive to BAT and thyroid hormones are 
permissive for UCP-1 expression (40). We found that peripheral administration of low-
dose T3 for five days increased food intake, without any alteration in BAT weight or 
UCP-1 mRNA levels. This suggests that the orexigenic effect of T3 is not secondary to 
changes in adaptive thermogenesis. Consistent with this, energy expenditure, measured as 
VO2, was unchanged following both acute and chronic peripheral administration of low-
dose T3. Thyrotoxicosis is associated with a significant increase in physical activity and 
this alteration in energy balance may contribute to the characteristic increased food 
intake. However, we found that administration of low-dose T3 increased feeding behavior 
without altering locomotor activity.  
 
Our studies demonstrate a role for the VMN in the feeding response to T3. Although 
early studies demonstrated that lesioning of the VMN produces hyperphagia and obesity 
(12), more recent work suggests a more complex role for the VMN in appetite regulation 
(41, 42). The VMN has projections to a number of hypothalamic nuclei involved in 
appetite regulation (43) and disruption of the VMN alters the expression of NPY mRNA 
in the ARC and NPY peptide in the PVN (44). However, it is unlikely that either the 
ARC or PVN are the primary site of action for the stimulatory feeding effects of T3, since 
peripheral T3 did not increase Egr-1-IR in either of these nuclei. In addition, injection of 
T3 into the ARC, unlike the VMN, did not affect feeding. The observed increase in food 
intake produced by T3 may not be mediated by well characterised neuropeptide 
regulators of feeding, such as POMC, AgRP or NPY, since their hypothalamic mRNA 
expression was unaltered following chronic T3 administration. However, changes in 
peptide synthesis and release may occur in the absence of altered mRNA expression. 
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Other molecules involved in the regulation of food intake, such as dopamine (45), 
serotonin (45), and brain-derived neurotrophic factor (46) are expressed in the VMN and 
their expression is altered by nutritional status. Therefore, the possible involvement of 
such neuromodulators of feeding cannot be excluded. 
 
Rats display a diurnal pattern in feeding and many neuropeptides involved in the 
regulation of food intake show a similar diurnal pattern in expression, for example, AgRP 
(47), NPY (48) and POMC (48). Campos-Barros et al (49) have shown that in rats, 
hypothalamic T3 concentrations peak just prior to the onset of the dark-phase, when 
feeding begins and hypothalamic D2 activity is maximal in the mid-dark phase. 
Consistent with this we demonstrated a diurnal variation in hypothalamic D2 mRNA, 
with levels greatest 4 hours into the dark phase. A previous study has shown that 
hypothalamic D2 mRNA expression increases following a prolonged, 72 hour fast (6). 
However, this duration of fasting was associated with pronounced suppression of the 
thyroid axis. We have shown that hypothalamic D2 mRNA expression is increased after 
only 12 hours of fasting, which is more relevant to the daily regulation of food intake. 
This increase in hypothalamic D2 mRNA levels with fasting may increase hypothalamic 
T3 levels and hence, stimulate appetite. One way to investigate this would be to inhibit 
the action of D2, for example with reverse T3, and examine the effects of this inhibition 
on food intake. 
 
Studies suggest that T4 is taken up by tanycytes from the cerebrospinal fluid and 
capillaries, and converted by D2 to the active hormone T3 for use in various 
hypothalamic regions (50). Therefore, T3 may be transported, possibly by tanycytes, to 
the VMN, to stimulate food intake. These data have led us to propose a hypothalamic 
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circuit, involving T3, which is regulated by daily energy requirements. The source of T3 
may be the peripheral circulation or locally derived in the hypothalamus by deiodination 
of T4 to T3 by D2. 
 
Previously, the role of thyroid hormones in energy balance has been largely confined to 
pathological states, such as hyperthyroidism. The effects of thyroid hormones on appetite 
have been presumed to be secondary to increased metabolism. Here, we propose a novel 
role for T3 in the regulation of daily food intake via the hypothalamic VMN. 
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Treatment Group 
 
Control 4.5 nmol/kg T3 9 nmol/kg T3 75 nmol/kg T3 
fT3 (pmol/L) 1.8 ± 0.2 2.5 ± 0.1 2.9 ± 0.1† 9.4 ± 0.6‡
fT4 (pmol/L) 15.3 ± 0.3 14.4 ± 0.6 7.7 ± 0.6‡ 1.2 ± 0.2‡
TSH (ng/ml) 1.9 ± 0.2 1.5 ± 0.1* 0.9 ± 0.1‡ 0.8 ± 0.1‡
Leptin (ng/ml) 2.7 ± 0.3 1.9 ± 0.2 2.4 ± 0.3 2.6 ± 0.3 
WAT (g) 1.9 ± 0.1 1.9 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 
BAT (g) 0.3 ± 0.10 0.3 ± 0.02 0.3 ± 0.02 0.3 ± 0.02 
POMC mRNA 
(R.U.) 
46.4 ± 3.3 38.6 ± 2.7 45.0 ± 2.0 51.0 ± 3.8 
AgRP mRNA 
(R.U.) 
123.0  ± 9.8 148.3 ± 15.0 141.7 ± 24.3 145.0 ± 10.5 
NPY mRNA 
(R.U.) 
104.9 ± 10.4 91.9 ± 9.5 92.7 ± 11.7 101.8 ± 10.6 
 
Table 1. 
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Table 1. Chronic T3 treatment: plasma thyroid hormones, body adiposity and 
hypothalamic neuropeptide expression. 
Ad libitum fed rats were injected once daily with s.c. T3 at doses indicated (nmol/kg) or 
vehicle for 5 days (n = 12/group). R.U. = relative units. *P < 0.05, †P < 0.005, ‡P < 0.0005 
vs controls. Results are mean ± S.E.M. 
 
Fig. 1. Peripheral administration of T3 increases food intake. 
Ad libitum fed rats received a single s.c. injection of T3 at the doses indicated (nmol/kg) or 
vehicle (V; control) (n = 12/group). Food intake A 0 to 2 hours and B 5 to 8 hours post-
injection.*P < 0.05 vs control. Results are mean ± S.E.M. 
 
Fig. 2. Chronic peripheral administration of T3 increases food intake and body 
weight. 
Ad libitum fed rats were injected once daily with s.c. T3 at the doses indicated (nmol/kg) or 
vehicle (V; control) for 5 days (n = 12/group).  Food intake and body weight were measured 
daily. A Mean daily food intake, B Cumulative food intake and C Cumulative body weight 
gain. A, B and C show values on day 5 of the study. †P < 0.005 and *P < 0.05 vs control. 
Results are mean ± S.E.M. 
 
Fig. 3. Peripheral T3 (4.5nmol/kg) stimulates feeding but does not alter energy 
expenditure. 
Oxygen consumption (VO2) at thermoneutrality (29oC) following a single s.c. injection of 
A 4.5 nmol/kg T3 (open circles) or vehicle (filled circles) or B BRL 35135 (open squares) 
or vehicle (filled squares); or 5 once daily injections of C 4.5 nmol/kg T3 (open circles) or 
vehicle (filled circles) and D 75 nmol/kg T3 (open triangles) or vehicle (filled triangles). 
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Animals were acclimatized to the chambers for 120 minutes prior to injection with T3 or 
vehicle at time zero (n = 8/group). Results are mean VO2 ± S.E.M. for each 30 minute 
period *P < 0.05, †P < 0.005 and ‡P < 0.0005 vs control.  
 
Fig. 4. Peripheral T3 (4.5nmol/kg) administration induces Egr-1 IR in the VMN and 
injection of T3 into the VMN stimulates feeding 
Representative example (bregma, -2.56mm) of Egr-1-IR in response to a s.c. injection of A 
vehicle and B T3 (4.5 nmol/kg), x100 magnification.  3V  = 3rd ventricle and dotted line 
delineates the VMN. C Food intake in ad libitum fed rats 1 hour post-injection of T3 (at the 
doses indicated (pmol)) or vehicle (V; control) into the VMN (n = 11 – 14/group), results 
are mean ± S.E.M. *P < 0.05 and ‡P < 0.0001 vs control.  
 
Fig. 5. Hypothalamic D2 mRNA increases with fasting and has a diurnal variation. 
A Hypothalamic D2 mRNA expression in rats fasted for 12 and 24 hours compared to ad 
libitum fed rat (n = 10/group). *P < 0.05 vs fed group. B Hypothalamic D2 mRNA 
expression over a 24 hour period (n = 10/group). Black line denotes duration of dark phase. 
*P < 0.05 vs D2 mRNA expression at all other light-phase time points. Results are mean ± 
S.E.M.  RU = relative units. 
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